HypothermiaNCT01996982
Study of a New Clinical Device for Reducing Body Core Temperature
A study testing CCS Device in people with Hypothermia, run by Seton Healthcare Family at 2 sites in United States.
Trial summary
This is a descriptive, nonrandomized, noninvasive, single-group, single-center pilot study of a Core Cooling System (CCS) device for reducing core body temperature in ICU patients at University Medical Center Brackenridge (UMCB) and Seton Medical Center Austin (SMCA). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypothermia
- What is being tested?
- CCS Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- 2 sitesUnited States
- Study dates
- Mar 2014to Jul 2015
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Admitted to UMCB ICU
- Sedated, intubated and or mechanically ventilated
- At least one core temperature measurement device in place (rectal, bladder, pulmonary artery) as standard of care
- Medical/surgical condition is stable enough to permit uninterrupted testing and observation for at least 24 hours
- No medical/surgical procedures are anticipated as necessary or scheduled during testing and observation period that would be affected by this protocol
- Vital signs and other parameters have been stable for at least 12 hours and there are no imminent indications of instability
- LAR available and willing to provide informed consent
Who cannot join
- Condition is too unstable to permit uninterrupted testing and observation
- Pregnant and breast feeding patients
- Patients that might worsen with TH, including coagulopathy (INR>1.5), thrombocytopenia (platelet count <100,000)
- Patients on antiplatelet therapy other than aspirin
- Patients on anticoagulants other than prophylactic low molecular weight heparin
- Patients on pressors to maintain blood pressure
- Patients with injuries to extremities that could preclude application of cooling mittens or socks to at least three extremities
- Patients on TH treatment for any other condition
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University Medical Center Brackenridge
Austin, Texas, 78701
Seton Medical Center
Austin, Texas, 78705
About this study
This is a descriptive, nonrandomized, noninvasive, single-group, single-center pilot study of a Core Cooling System (CCS) device for reducing core body temperature in ICU patients at University Medical Center Brackenridge (UMCB) and Seton Medical Center Austin (SMCA). The proposed research on human subjects will provide data that will be used to improve a specialized human heat transfer technique/device. By stimulating specialized blood vessels (arteriovenous anastomoses) AVAs in the palm of the hand, it is possible to greatly increase local blood flow and thus greatly increase the potential for effective heat transfer between the environment and body.
The hypothesis of this trial is that the Core Cooling System (CCS) will prove to be a practical, safe, and effective method to raise or lower body temperature in critically ill patients.
Read the detailed description
Introduction:
The ability to manipulate body core temperatures quickly and effectively would impact a number of fields, with truly transformative potential. By far the best way to effect a change in body temperature is perfusion with cooled or warmed blood because the vasculature of the human body equilibrates magnificently well with the body and especially the body core tissues due to the diffuse microcirculation. This process is quite invasive, however, and noninvasive techniques to date have mostly revolved around various surface heat transfer mechanisms that ultimately rely on relatively inferior conduction heat transfer.
Grahn, et al., at Stanford University have identified a new technique to increase the rate of heat transfer between the skin and the body core by up to a factor of ten by harnessing the convective power of the circulatory system in a completely noninvasive way [1, 2]. Our system is derivative of the Stanford device, but different in many significant ways.
A well-understood and thus modifiable system capable of rapid artificial heat transfer has almost limitless potential applications, including treatment of acute brain trauma (where the single greatest challenge to treatment is inducing immediate hypothermia), athletic performance enhancement, military operations, and enhancement of industries in which workers are subject to extreme thermal stress.
Description of the Technology/Device:
The technology works as a two-step process, consisting of first stimulating the blood flow to the AVAs and second cooling the glabrous skin through which blood is flowing. Accordingly, the device consists of two components: first a blood flow stimulation source, and second a surface heat exchanger to chill the glabrous skin and thereby the blood flowing through it that subsequently flows back to the body core, where it cools those tissues.
Two separate means of stimulation will be tested in the trial:
- Transcutaneous Electrical Nerve Stimulation (TENS) - An FDA-approved TENS unit sends a current via surface electrodes through the skin to stimulate the nerves that control the state of AVA vasoconstriction. This stimulation will create a vasodilation effect in the AVAs, allowing an increase in blood flow.
- Mild thermal stimulation along the skin overlying the cervical spine to send a control signal to vasodilate the AVAs and provide an increased blood flow to glabrous skin. An FDA-approved electric heating pad is used for this purpose at a temperature of 42°C or lower.
Cooling will be accomplished by applying water perfusion bladders to the hands and feet. The water will recirculate through the bladders to a holding tank with an internal pump, and a thermoelectric cooler regulates the water temperature. The water temperature will be at 20°C or higher.
Research Incentive:
The AVA structures in glabrous (non-hairy) skin are one component of the body's natural thermoregulatory system. The anatomy and morphology of AVAs have been described to a great extent in the literature, e.g. Sherman [6]. Putative pre-AVA sphincters are thought to be the primary controllers of perfusion through AVAs, regardless of the level of AVA vasodilation. If the AVAs are completely dilated, but the sphincters closed, blood will pool in the dilated AVAs, but the flow of blood, which is essential for heat exchange with the core, will be minimal. In contrast to perfusion of capillaries, which is largely regulated by local conditions, flow through AVAs appears to be mostly centrally mediated, controlled primarily by the vasoconstrictor tone imparted by rich sympathetic innervation [7-10]. The sympathetic vasoconstrictor tone, which appears to oscillate in a characteristic manner over time, is controlled by the central nervous system's homeostatic centers that respond to various centrally located core temperature receptors. The complete inner workings of this control system and its effector mechanisms are not completely understood or quantified, and other factors influence AVA blood flow to some degree, such as local skin temperatures, the presence of vasoactive metabolites, level of exercise, and stimulation of various peripheral thermal sites. Recent work in the Diller lab has indicated the potential inherent in the latter. The lab has identified regions of the skin that may be non-energetically thermally stimulated (heating over a small area so as not to warm a significant volume) to induce AVA vasodilation. We hypothesize these sites contain important thermoafferent sensors that impact the central component (hypothalamic) of the governing controller.
The ability to induce mild hypothermia from a normothermic state represents the application of greatest interest to our research group. If optimally developed, a device capable of inducing only a 2-4°C decrease in body core temperature could have a huge impact in treatment of various medical disease states and/or emergencies, including cardiac arrest, severe brain injury, and stroke. It is well known that tissue death due to traumatic physical injury and/or ischemia can be decreased with therapeutic hypothermia because of the temperature dependence of cellular metabolism and the complex, destructive biochemical processes that occur in damaged tissues [12].
Therapeutic hypothermia has been shown to have a great effect in various animal models; however, translation of these results to the clinical domain has been very difficult. Aside from any possible interspecies physiological differences, researchers are able to produce injury and cool the core of the research animals in a very controlled manner, and most importantly, cooling is induced very soon after injury. From these experiments, it has been suggested that a "window of opportunity" exists of about 90 minutes post injury, after which little to no therapeutic effect occurs from mild hypothermia. Moreover, this 90-minute threshold may itself be a stretch, and cooling within a 60-minute window may be most appropriate. Clinically, cooling within the former and surely the latter windows has almost never been achieved. There are a number of reasons for this: the time between injury and mobilization of the patient, transportation to an emergency care facility, initial assessment of the patient in the hospital setting, and most importantly for physiological science, a lack of fast and effective methods to cool the body core. Due to simple size and geometry, the human body is much more difficult to heat or cool than, for example, the rat model. This is especially true for conductive heat transfer mechanisms (which is what most current noninvasive therapeutic hypothermia implementations are based on) because of the relatively small ratio of surface area to thermal mass volume [3].
We hope that the problem of rapid core temperature manipulation can be drastically improved upon, specifically by utilizing convective heat transfer through AVAs of glabrous skin. In these experiments, we believe an optimized combinatorial protocol utilizing large coverage of glabrous regions (both palms plus soles of the feet), manipulation of mean skin temperature, and especially optimized stimulation of peripheral thermoafferent sensors located in regions of the body such as along the spine, can allow for mild hypothermia induction in spite of the conflict with the thermoregulatory controller. We especially hope that manipulation of important thermoafferents will allow us to "trick" the controller and bypass its effective vasoconstrictive signal.
- Conditions
- Hypothermia
- Being tested
- CCS Device
- Keywords
- Induced therapeutic hypothermia
- Medical subject headings
- Hypothermia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CCS DeviceDevice
Core Cooling System Device
| Study group | Role | What they receive |
|---|---|---|
| Device | Experimental | CCS Device application Receives: Device: CCS Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adverse Events From Application and Use of the Core Cooling System (CCS) Device.
- Assess and capture all adverse events (if any) from application and use of the CCS device.
- Also assess CCS device interference with participant's standard of care.
Measured: 1 year after the enrollment is closed
Secondary outcomes (1)
Number of Participant's With Adverse Events From Induction of Therapeutic Hypothermia (TH).
Assess and capture all adverse events from induction of TH with CCS device.
Measured: 1 year after the enrollment is closed.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2013 (estimated)
- Study startMar 2014
- Primary completionJul 2015
- Study completionJul 2015
Why it stopped: The Prinicipal Investigator left the organization and decided to close the trial
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for HypothermiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seton Healthcare Family
- Sponsor type
- University, hospital or other
- Collaborators
- University of Texas at Austin
- Responsible party
- Sponsor
- Investigators
- Alex B Valadka, MD, FACS, Principal investigator, Seton Healthcare Family
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01996982
- Sponsor's protocol ID
- CR-13-148
- Status last verified
- Jul 2019
- First submitted
- 4 Nov 2013
- Last updated
- 29 Jul 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Grahn DA, Cao VH, Heller HC. Heat extraction through the palm of one hand improves aerobic exercise endurance in a hot environment. J Appl Physiol (1985). 2005 Sep;99(3):972-8. doi: 10.1152/japplphysiol.00093.2005. Epub 2005 May 5.
PubMed 15879169Grahn D, Brock-Utne JG, Watenpaugh DE, Heller HC. Recovery from mild hypothermia can be accelerated by mechanically distending blood vessels in the hand. J Appl Physiol (1985). 1998 Nov;85(5):1643-8. doi: 10.1152/jappl.1998.85.5.1643.
PubMed 9804564Hales JR, Fawcett AA, Bennett JW, Needham AD. Thermal control of blood flow through capillaries and arteriovenous anastomoses in skin of sheep. Pflugers Arch. 1978 Dec 15;378(1):55-63. doi: 10.1007/BF00581958.
PubMed 569825SHERMAN JL Jr. NORMAL ARTERIOVENOUS ANASTOMOSES. Medicine (Baltimore). 1963 Jul;42:247-67. doi: 10.1097/00005792-196307000-00001. No abstract available.
PubMed 14046752Krogstad AL, Elam M, Karlsson T, Wallin BG. Arteriovenous anastomoses and the thermoregulatory shift between cutaneous vasoconstrictor and vasodilator reflexes. J Auton Nerv Syst. 1995 Jun 25;53(2-3):215-22. doi: 10.1016/0165-1838(94)00178-m.
PubMed 7560758Bergersen TK, Eriksen M, Walloe L. Local constriction of arteriovenous anastomoses in the cooled finger. Am J Physiol. 1997 Sep;273(3 Pt 2):R880-6. doi: 10.1152/ajpregu.1997.273.3.R880.
PubMed 9321863Wissler EH. A quantitative assessment of skin blood flow in humans. Eur J Appl Physiol. 2008 Sep;104(2):145-57. doi: 10.1007/s00421-008-0697-7. Epub 2008 Feb 27.
PubMed 18301912Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241.
PubMed 19535947Venturi ML, Attinger CE, Mesbahi AN, Hess CL, Graw KS. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol. 2005;6(3):185-94. doi: 10.2165/00128071-200506030-00005.
PubMed 15943495
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of a New Clinical Device for Reducing Body Core Temperature
- ClinicalTrials.gov ID
- NCT01996982
- Acronym / sponsor ID
- CR-13-148
- Conditions
- Hypothermia
- Keywords
- Induced therapeutic hypothermia
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The Prinicipal Investigator left the organization and decided to close the trial
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Seton Healthcare FamilyUniversity, hospital or other
- Collaborators
- University of Texas at Austin
- Study start
- Mar 2014
- Primary completion
- Jul 2015 (actual)
- Study completion
- Jul 2015 (actual)
- First posted
- 27 Nov 2013 (estimated)
- Results
- Posted 20 Jun 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a descriptive, nonrandomized, noninvasive, single-group, single-center pilot study of a Core Cooling System (CCS) device for reducing core body temperature in ICU patients at University Medical Center Brackenridge (UMCB) and Seton Medical Center Austin (SMCA). The proposed research on human subjects will provide data that will be used to improve a specialized human heat transfer technique/device. By stimulating specialized blood vessels (arteriovenous anastomoses) AVAs in the palm of the hand, it is possible to greatly increase local blood flow and thus greatly increase the potential for effective heat transfer between the environment and body.
The hypothesis of this trial is that the Core Cooling System (CCS) will prove to be a practical, safe, and effective method to raise or lower body temperature in critically ill patients.
Detailed description
Introduction:
The ability to manipulate body core temperatures quickly and effectively would impact a number of fields, with truly transformative potential. By far the best way to effect a change in body temperature is perfusion with cooled or warmed blood because the vasculature of the human body equilibrates magnificently well with the body and especially the body core tissues due to the diffuse microcirculation. This process is quite invasive, however, and noninvasive techniques to date have mostly revolved around various surface heat transfer mechanisms that ultimately rely on relatively inferior conduction heat transfer.
Grahn, et al., at Stanford University have identified a new technique to increase the rate of heat transfer between the skin and the body core by up to a factor of ten by harnessing the convective power of the circulatory system in a completely noninvasive way [1, 2]. Our system is derivative of the Stanford device, but different in many significant ways.
A well-understood and thus modifiable system capable of rapid artificial heat transfer has almost limitless potential applications, including treatment of acute brain trauma (where the single greatest challenge to treatment is inducing immediate hypothermia), athletic performance enhancement, military operations, and enhancement of industries in which workers are subject to extreme thermal stress.
Description of the Technology/Device:
The technology works as a two-step process, consisting of first stimulating the blood flow to the AVAs and second cooling the glabrous skin through which blood is flowing. Accordingly, the device consists of two components: first a blood flow stimulation source, and second a surface heat exchanger to chill the glabrous skin and thereby the blood flowing through it that subsequently flows back to the body core, where it cools those tissues.
Two separate means of stimulation will be tested in the trial:
- Transcutaneous Electrical Nerve Stimulation (TENS) - An FDA-approved TENS unit sends a current via surface electrodes through the skin to stimulate the nerves that control the state of AVA vasoconstriction. This stimulation will create a vasodilation effect in the AVAs, allowing an increase in blood flow.
- Mild thermal stimulation along the skin overlying the cervical spine to send a control signal to vasodilate the AVAs and provide an increased blood flow to glabrous skin. An FDA-approved electric heating pad is used for this purpose at a temperature of 42°C or lower.
Cooling will be accomplished by applying water perfusion bladders to the hands and feet. The water will recirculate through the bladders to a holding tank with an internal pump, and a thermoelectric cooler regulates the water temperature. The water temperature will be at 20°C or higher.
Research Incentive:
The AVA structures in glabrous (non-hairy) skin are one component of the body's natural thermoregulatory system. The anatomy and morphology of AVAs have been described to a great extent in the literature, e.g. Sherman [6]. Putative pre-AVA sphincters are thought to be the primary controllers of perfusion through AVAs, regardless of the level of AVA vasodilation. If the AVAs are completely dilated, but the sphincters closed, blood will pool in the dilated AVAs, but the flow of blood, which is essential for heat exchange with the core, will be minimal. In contrast to perfusion of capillaries, which is largely regulated by local conditions, flow through AVAs appears to be mostly centrally mediated, controlled primarily by the vasoconstrictor tone imparted by rich sympathetic innervation [7-10]. The sympathetic vasoconstrictor tone, which appears to oscillate in a characteristic manner over time, is controlled by the central nervous system's homeostatic centers that respond to various centrally located core temperature receptors. The complete inner workings of this control system and its effector mechanisms are not completely understood or quantified, and other factors influence AVA blood flow to some degree, such as local skin temperatures, the presence of vasoactive metabolites, level of exercise, and stimulation of various peripheral thermal sites. Recent work in the Diller lab has indicated the potential inherent in the latter. The lab has identified regions of the skin that may be non-energetically thermally stimulated (heating over a small area so as not to warm a significant volume) to induce AVA vasodilation. We hypothesize these sites contain important thermoafferent sensors that impact the central component (hypothalamic) of the governing controller.
The ability to induce mild hypothermia from a normothermic state represents the application of greatest interest to our research group. If optimally developed, a device capable of inducing only a 2-4°C decrease in body core temperature could have a huge impact in treatment of various medical disease states and/or emergencies, including cardiac arrest, severe brain injury, and stroke. It is well known that tissue death due to traumatic physical injury and/or ischemia can be decreased with therapeutic hypothermia because of the temperature dependence of cellular metabolism and the complex, destructive biochemical processes that occur in damaged tissues [12].
Therapeutic hypothermia has been shown to have a great effect in various animal models; however, translation of these results to the clinical domain has been very difficult. Aside from any possible interspecies physiological differences, researchers are able to produce injury and cool the core of the research animals in a very controlled manner, and most importantly, cooling is induced very soon after injury. From these experiments, it has been suggested that a "window of opportunity" exists of about 90 minutes post injury, after which little to no therapeutic effect occurs from mild hypothermia. Moreover, this 90-minute threshold may itself be a stretch, and cooling within a 60-minute window may be most appropriate. Clinically, cooling within the former and surely the latter windows has almost never been achieved. There are a number of reasons for this: the time between injury and mobilization of the patient, transportation to an emergency care facility, initial assessment of the patient in the hospital setting, and most importantly for physiological science, a lack of fast and effective methods to cool the body core. Due to simple size and geometry, the human body is much more difficult to heat or cool than, for example, the rat model. This is especially true for conductive heat transfer mechanisms (which is what most current noninvasive therapeutic hypothermia implementations are based on) because of the relatively small ratio of surface area to thermal mass volume [3].
We hope that the problem of rapid core temperature manipulation can be drastically improved upon, specifically by utilizing convective heat transfer through AVAs of glabrous skin. In these experiments, we believe an optimized combinatorial protocol utilizing large coverage of glabrous regions (both palms plus soles of the feet), manipulation of mean skin temperature, and especially optimized stimulation of peripheral thermoafferent sensors located in regions of the body such as along the spine, can allow for mild hypothermia induction in spite of the conflict with the thermoregulatory controller. We especially hope that manipulation of important thermoafferents will allow us to "trick" the controller and bypass its effective vasoconstrictive signal.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Device | Experimental | Device: CCS DeviceCCS Device application |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥ 18 years
- Admitted to UMCB ICU
- Sedated, intubated and or mechanically ventilated
- At least one core temperature measurement device in place (rectal, bladder, pulmonary artery) as standard of care
- Medical/surgical condition is stable enough to permit uninterrupted testing and observation for at least 24 hours
Key exclusion criteria (8 listed)
- Condition is too unstable to permit uninterrupted testing and observation
- Pregnant and breast feeding patients
- Patients that might worsen with TH, including coagulopathy (INR>1.5), thrombocytopenia (platelet count <100,000)
- Patients on antiplatelet therapy other than aspirin
- Patients on anticoagulants other than prophylactic low molecular weight heparin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CCS DeviceCore Cooling System Device | Device | Device |
Primary outcome
Adverse Events From Application and Use of the Core Cooling System (CCS) Device.
Time frame: 1 year after the enrollment is closed
1. Assess and capture all adverse events (if any) from application and use of the CCS device. 2. Also assess CCS device interference with participant's standard of care.
1 secondary outcome
Number of Participant's With Adverse Events From Induction of Therapeutic Hypothermia (TH).
Time frame: 1 year after the enrollment is closed.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 15879169Grahn DA, Cao VH, Heller HC. Heat extraction through the palm of one hand improves aerobic exercise endurance in a hot environment. J Appl Physiol (1985). 2005 Sep;99(3):972-8. doi: 10.1152/japplphysiol.00093.2005. Epub 2005 May 5.
- Background: PubMed 9804564Grahn D, Brock-Utne JG, Watenpaugh DE, Heller HC. Recovery from mild hypothermia can be accelerated by mechanically distending blood vessels in the hand. J Appl Physiol (1985). 1998 Nov;85(5):1643-8. doi: 10.1152/jappl.1998.85.5.1643.
- Background: PubMed 569825Hales JR, Fawcett AA, Bennett JW, Needham AD. Thermal control of blood flow through capillaries and arteriovenous anastomoses in skin of sheep. Pflugers Arch. 1978 Dec 15;378(1):55-63. doi: 10.1007/BF00581958.
- Background: PubMed 14046752SHERMAN JL Jr. NORMAL ARTERIOVENOUS ANASTOMOSES. Medicine (Baltimore). 1963 Jul;42:247-67. doi: 10.1097/00005792-196307000-00001. No abstract available.
- Background: PubMed 7560758Krogstad AL, Elam M, Karlsson T, Wallin BG. Arteriovenous anastomoses and the thermoregulatory shift between cutaneous vasoconstrictor and vasodilator reflexes. J Auton Nerv Syst. 1995 Jun 25;53(2-3):215-22. doi: 10.1016/0165-1838(94)00178-m.
- Background: PubMed 9321863Bergersen TK, Eriksen M, Walloe L. Local constriction of arteriovenous anastomoses in the cooled finger. Am J Physiol. 1997 Sep;273(3 Pt 2):R880-6. doi: 10.1152/ajpregu.1997.273.3.R880.
- Background: PubMed 18301912Wissler EH. A quantitative assessment of skin blood flow in humans. Eur J Appl Physiol. 2008 Sep;104(2):145-57. doi: 10.1007/s00421-008-0697-7. Epub 2008 Feb 27.
- Background: PubMed 19535947Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241.
- Background: PubMed 15943495Venturi ML, Attinger CE, Mesbahi AN, Hess CL, Graw KS. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol. 2005;6(3):185-94. doi: 10.2165/00128071-200506030-00005.
- Individual participant dataSharing planned: No
Related trials for Hypothermia
Not yet recruiting
Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPESPLIT)
Pediatric Liver Transplantation
RecruitingPhase 2/3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
Hypoxic-Ischemic Encephalopathy
RecruitingPhase 2
The PROTECT-HIE Pilot Trial
Hypoxic-ischemic Encephalopathy (HIE)
Not yet recruiting
Effect of Laryngeal Mask Airway vs Endotracheal Tube on Hypothermia in Laparoscopic Hernia Surgery
Perioperative Hypothermia, Hernia, Inguinal
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alex B Valadka, MD, FACS principal investigator
Seton Healthcare Family
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CCS Device in people with Hypothermia, run by Seton Healthcare Family at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Jun 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adverse Events From Application and Use of the Core Cooling System (CCS) Device. (time frame: 1 year after the enrollment is closed). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01996982, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2019.